GT Biopharma shares rise 10.61% intraday after submitting IND application for GTB-5550 solid tumor therapy.

GT Biopharma Inc. surged 10.61% intraday after announcing the submission of an investigational new drug (IND) application for GTB-5550 TriKE, a B7-H3-targeted natural killer cell engager for solid tumor cancers. The IND submission, made in December 2025, marks the company’s expansion into a broader patient population, targeting a segment of the $362 billion global solid tumor market. The press release highlighted preliminary cash reserves of $7 million, extending the company’s runway into Q3 2026, which bolstered investor confidence. CEO Michael Breen emphasized the strategic significance of GTB-5550, noting its potential to leverage clinical learnings from GTB-3650 trials in hematologic malignancies. The stock’s sharp intraday gain aligns with the positive reception of the IND filing, reflecting optimism about the therapy’s development and market potential.